1. Increasing Prevalence of Migraine Expected to Drive the Market

Ask our Research Analyst about the latest Market Trends

2. Asia-Pacific to Emerge as the Fastest-Growing Region

Asia-Pacific (APAC) is quickly emerging as the fastest-growing region in the Migraine Therapeutics Market and is expected to register a CAGR of about 6% during the forecast period. The primary reason for the growth is the increasing number of migraine cases and public awareness about the disease. India and China are the major markets in this region, as the prevalence of migraine is high in these countries. The increasing focus on new product launches and high market penetration of drug manufacturers I expected to aid the growth of the market in APAC, during the forecast period.

3. Unmet Needs in the Field of Migraine Therapeutics

Many major unmet needs have been identified in the field of migraine therapeutics, including acute drugs that work for patients who are either unresponsive to triptans or people with a risk of cardiovascular complications. Improving physician instruction in diagnosing and treating severe and bearable migraine, and effective prophylactic cures for patients suffering from highly recurrent and chronic migraine will lead the market to grow with a high CAGR.

Buy the full report to know more about the Market Segmentation

 4. Leading Companies of the Market Studied

The report also examines the role of the leading market players involved in the industry. Some of the key players listed in the study are:

• Allergan
• Amirall
• AstraZeneca
• CoLucid Pharmaceuticals
• GlaxoSmithKline
• Merck
• NeurAxon
• NuPathe
• OptiNose
• Pfizer
• RedHill Biopharma
• Revance Therapeutics
• SUDA
• Teva
• Vernalis
• Zogenix

Access the full report to know more about each Key Player and the Competitive Landscape

About the Migraine Therapeutics Market

The migraine therapeutics market is expected to register a CAGR of 8.4% during the forecast period. Migraine is a complex neurological condition, characterized by frequent headaches that can last between four and 72 hours. The pain is often unilateral and pulsating in nature, which can often worsen by physical activity. In most cases, migraine is associated with symptoms, such as photophobia, phonophobia, osmophobia, nausea, vomiting, loss of appetite, and sometimes sensory disturbances.

Get the full report from Mordor Intelligence to know more about the Migraine Therapeutics Market

Mordor Intelligence is a market intelligence and advisory firm operating in 14 industry segments, serving over 600 clients worldwide.

The post Things to know about the Migraine Therapeutics Market appeared first on Official Blog | Mordor Intelligence.